join catalyst month
next chapter begin believ chapter one
improv execut innov growth believ risk/reward attract
investor read preced sentenc like doubt statement
believ investor skeptic dont believ abil
acceler growth time felt like two step forward one step
back new decad think medtron time shine there catalyst
nearli everi month transit ceo geoff martha april bi-
annual investor day june think show back reiter
overweight rate also top pick
attract risk/reward current level
believ risk/reward profil attract share trade
discount med-tech stock also mani consum stapl stock
investor seem skeptic compani abil acceler growth
pipelin plu mayb tuck-in drive acceler top-lin growth
deep broad pipelin believ top line acceler
next sever year potenti north there catalyst almost everi month
see catalyst roadmap insid new cardiac rhythm devic robot turn
around diabet potenti shot like renal denerv much in-
bound ceo geoff martha express increas willing consid tuck-in
 could provid increment growth/valu
acceler top line drive pe expans closer peer
catalyst occur case revenu acceler becom tangibl
grow sale trade thu investor forese
acceler case valuat gap narrow time pt appli
pe calendar
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
idc link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
feb advanc technolog treatment diabet attd
american colleg cardiolog
apr societi gastrointestin endoscop surgeon sage
end year robot initi launch
april geoff martha take ceo
may result guidanc
next chapter begin believ chapter one
improv execut innov growth catalyst nearli everi
month year believ bring greater appreci depth
breadth pipelin potenti revenu acceler ahead
turn lead expand pe multipl reaffirm overweight rate
geoff martha take rein ceo omar ishrak april martha
previous serv evp presid restor therapi group rtg
becam presid member board director effect novemb
expect continu martha take particularli relat focu intern
innov martha inherit deep broad pipelin one
express great confid howev expect martha bring crisp execut
greater focu tuck-in believ success strategi
look number catalyst fill calendar creat
tangibl roadmap investor acceler top line growth see catalyst
nearli everi month year signific event like
june analyst meet newli appoint ceo geoff martha outlin
strategi fulli unveil pipelin
roadmap expand pe
north american neuromodul societi nan unveil next-gener spinal-cord stimul devic
advanc technolog treatment diabet attd plan data pump
american colleg cardiolog plan present renal denerv data simplic spyral htn-off
trial also expect addit data transcathet valv program well cvg pipelin updat
societi american gastrointestin endoscop surgeon sage discuss robot
initi launch hugo surgic robot end fiscal year fda approv interstim micro surescan mri lead
geoff martha offici take ceo
heart rhythm societi hr launch number new devic expect approv
end begin includ micra av reveal linq ii icm cobalt/crom famili icds/crt-d
medtron result guidanc extra sell week
american diabet associ ada meet clinic data approv near end region earli
result extra sell week
transcathet cardiovascular therapeut tct like investor brief review medtron cvg pipelin
north american spine societi nass like investor brief review medtron mazor robot spine busi
time reflect year progress pipelin
sale product categori
sale geographi
product includ devic design diagnos treat manag heart rhythm disord heart failur
implant cardiac monitor left ventricular assist devic lvad
coronari structur heart product treat coronari arteri diseas heart valv disord includ coronari stent cathet transcathet
aortic valv replac surgic ablat product brand includ corevalv line transcathet
aortic valv resolut drug-elut stent
aortic peripher vascular aortic peripher vascular product treat aortic diseas peripher vascular diseas venou diseas via
graft stent system drug coat balloon carotid arteri embol protect
product includ surgic product stapl devic vessel wound closur electro surgeri
product divis also includ hernia gynecolog product
respiratori monitor airway manag product devic minim invas gastrointestin
procedur treatment renal diseas
spinal implant treat degen disc diseas spinal deform spinal tumor fractur spine
stenosi spine also includ product facilit less invas thoracolumbar surgeri treat condit
cervic region spine biolog solut infus deminer bone matrix product
neurovascular product coil stent devic treat brain aneurysm stroke brain
modul product use treat parkinson epilepsi ocd neurosurgeri product includ
product treat ent diseas control pelvic gastric condit interstim system specialti
surgic product surgeri system aquamanti system
spinal cord stimul implant drug infus system chronic pain intervent product
diabet product design type type ii diabet patient includ insulin pump continu glucos
monitor system diabet manag softwar minim line insulin pump major brand
busi segment
januari leav investor feel stimul medtron
particip broker confer earli month expect
manag provid gener thought balanc fiscal year
comment posit pipelin unlik last year anticip neg
commentari break-out session next fiscal year note
extra sell week help optic top line less bottom line
conjunct north american
host
neuromodul societi nan meet highlight also
anticip possibl ce mark european approv next-gener sacral
watch
updat percept deep brain stimul db expect launch near end
 earli
nan annual meet world largest assembl field neuromodul
medtron princip product neuromodul includ
spinal cord stimul product includ recharg non-recharg
devic larg select lead use treat chronic back and/or limb pain
competitor includ abbott nuvectra
includ medtron activa famili deep brain
stimul db devic parkinson diseas tremor epilepsi dystonia
obsess compuls disord primari competitor db includ abbott boston
plan host investor brief conjunct meet also
expect updat broader neuromodul portfolio includ product
treatment neurolog disord
spinal cord stimul product medtron plan unveil next-gener spinal cord
stimul system manag provid littl detail around new
system thu far note expect also releas new version snapshot
report softwar everi month increment featur cohort report
extern sensor pain monitor time also work close
loop spinal cord stimul use evok compound action potenti ecap
maintain therapeut activ though formal timelin given
radiofrequ ablat may provid updat accurian radiofrequ
ablat platform nerv tissu announc last year nan confer
accurian featur radiofrequ probe intern cool creat larger spheric
lesion compet avano coolief well tradit rf ablat
deep brain stimul medtron activa deep brain stimul db system first
approv treatment essenti tremor tremor associ
parkinson diseas pd fda subsequ approv db gener case
pd dystonia within year db approv patient
treat pd essenti tremor db becam standard treatment pd
sole manufactur db neurostimul
abbott st jude infin db approv pd boston scientif vercis db
also approv pd
activa db neurostimul current approv pd essenti tremor epilepsi
well hde dystonia ocd
approv humanitarian devic exempt hde
despit medtron head start db competit pressur abbott boston
scientif led recent declin busi increment innov
includ new clinician patient programm well new indic
epilepsi help slow headwind meaning innov take
place near end fiscal beyond
first percept db primari cell system expect launch near end fiscal
begin fiscal devic sens enabl mean sens
record patient brain activ work toward eventu launch
closed-loop system abl automat adjust stimul respons patient
also plan launch direct lead allow omni-
direct target stimul medtron hope launch lead fiscal
longer term compani anticip launch cranial-mount db system
devic much smaller recharg devic elimin lead tunnel
chest neck stimul
omnidirect
complex tunnel
pector implant
medtron interstim first sacral neuromodul snm system approv
fda septemb treat refractori urgency-frequ urg urinari
incontin indic use subsequ expand includ non-
obstruct urinari retent fecal incontin medtron second
iter interstim ii system fda approv juli
enjoy monopoli snm market year
recent attract entrant million snm market septemb
axon modul technolog receiv fda approv snm system r-
snm clinic indic fecal incontin fi axon subsequ receiv
fda approv overact bladder oab urinari retent ur indic
howev plan releas anoth iter interstim come
month micro expect volum roughli smaller interstim ii
implant puls gener expect recharg also expect
system full bodi mri compat
octob announc file pma supplement interstim micro
surescan mri lead expect fda approv late spring
expect receiv ce mark interstim micro januari
guidanc novemb provid guidanc manag
expect overal organ sale growth divis expect organ growth
cardiac vascular group cvg minim
therapi group mtig restor therapi group rtg
diabet busi expect flat slightli strong growth intern
offset declin unit state reflect deferr revenu due
technolog upgrad plan fx expect headwind manag
expect slight improv oper margin off-set impact currenc headwind
adjust ep expect includ neg impact
fx model midpoint rang
current guidanc expect organ sale growth
divis expect though divis chang cvg
mitg rtg growth diabet grow
low-single-digit reflect strong intern growth offset weaker us
perform fx expect headwind expect oper
margin expand fx neutral adjust ep expect
includ fx headwind model
feb advanc technolog treatment
watch
possibl minim trial data europ
updat guardian cgm non-adjunct label file juli
comment expect data present februari
advanc technolog treatment diabet confer madrid spain
howev manag note may us pivot data may
european data due cut-off data submiss look program
januari see refer data howev check
whether last-minut addit schedul
import
medtron busi face competit headwind compani await upcom
product approv minim advanc hybrid close loop system
bluetooth technolog state expect receiv regulatori
approv pump around end manag specifi
geograph region ce mark fda approv note final
date enrol technolog upgrad program signal us likelihood
fda approv like date medtron end april
june investor brief held conjunct american diabet
associ ada meet review expect data
expect system time-in-rang greater said believ
invest commun somewhat skeptic achiev goal way
comparison nih-fund diabet close loop trial particip use tandem
diabet slim insulin pump control-iq six month averag time-in-
rang per day time-in-rang overnight
american colleg cardiolog
watch
spyral htn-off pivot trial data renal denerv
updat cardiac vascular group
confer focus diagnost therapeut pharmaceut medic
devic treatment cardiovascular diseas past late break
data releas confer plan present data
symplic spyral htn-off trial renal denerv also expect
addit data transcathet valv program well cvg pipelin updat
often devic compani host investor brief conjunct
confer
renal denerv opportun resurrect dj vu
renal denerv potenti back view renal denerv uncertain
long-term potenti opportun even initi short term clinic data good
signific market build opportun need happen along gather
around seven year ago signific enthusiasm around multi-billion market
prospect renal denerv ablat renal arteri reduc blood pressur
patient resist hypertens time expect market opportun
treatment resist hypertens billion three major cardiac
compani boston scientif st jude renal denerv program
place mani compani jump bandwagon covidien
mani start-up
acquir program million ardian deal boston
scientif acquir program million plu mileston
million vessix deal covidien acquir program maya medic
million cash million mileston
market enthusiasm significantli cool announc januari
medtron symplic trial fail meet primari endpoint chang
offic systol blood pressur osbp month initi trial shown promis result
trial first blind studi compar renal denerv sham
procedur result show renal denerv fail demonstr statist
signific blood-pressure-low effect compar sham treatment
went back draw board attempt anoth shot
redesign symplic spyral system multi-electrod cathet allow convent
distal renal arteri ablat
multi-electrod cathet simultan
ablat electrod
multi-sensor feedback control energi deliveri
on-going random sham-control spyral htn global clinic program design
measur safeti efficaci symplic spyral renal denerv system
absenc spyral htn-off presenc spyral htn-on anti-
may affect result includ studi popul look
moder hypertens patient instead sever procedur method medic
chang adher patient known non-adher
osbp hg hg odbp hg
abpm average sbp hg hg
osbp month
hour abpm month
hour abpm month
major advers event month new
major advers event month
main arteri
spyral htn-off april announc fda approv begin pivot trial evalu
symplic spyral renal denerv system patient high blood pressur absenc anti-hypertens
medic trial random sham-control studi patient site europ
australia japan primari efficaci endpoint blood pressur three month primari safeti
endpoint incid major advers event one-month post random manag expect present
data compon march
spyral htn-on novemb began fda-approv trial evalu symplic spyral renal
denerv system patient high blood pressur alreadi prescrib anti-hypertens medic trial
random sham-control studi random patient center japan europ
australia canada patient follow three year primari safeti endpoint includ major advers event
one month new renal arteri stenosi six month primari efficaci endpoint ambulatori blood
pressur abpm six month subject prescrib stabl regimen three anti-hypertens medic
includ diuret calcium channel blocker ace/arb inhibitor beta blocker compani expect complet
enrol first half approv
jung gechter jl wunder et al resist hypertens assess adher toxicolog urin analysi
apr societi gastrointestin endoscop surgeon
watch
updat sage robot platform
societi gastrointestin endoscop surgeon sage confer focus
minim invas surgeri includ robot past compani host
investor meet conjunct meet
meet like content rel medtron hugo robotic-assist surgeri
ra platform well competit program
end year robot initi launch
watch
commenc initi launch hugo robotic-assist surgeri ra platform
end year
plan commenc hugo launch intern fiscal
end april allow begin gather experience/data
system
term timelin plan ce mark submiss
expect file us studi would allow place
initi system train gather clinic data receiv ce
fall calendar would
remind unveil hugo ra analyst meet septemb
meet highlight key attribut system see figur
provid think around timelin mileston potenti financi impact
comment expect hugo ra provid increment growth less
minim invas therapi group mitg growth rate given
limit approv time-frame note would rel guidanc
medtron expect increment contribut
base base
word expect prove correct number could get big fast even
assum contribut low end rang would impli rate
growth rate meaning busi group
april geoff martha take ceo
august announc plan ceo leadership transit current
ceo omar ishrak approach mandatori retir age believ martha
bring renew spirit one focus innov execut
effect novemb geoff martha age becam presid member
board director effect april martha succeed omar ishrak ceo omar
ishrak assum newli creat posit execut chairman expect
year provid counsel oversight leadership team ensur smooth ceo
success drive execut long-term strateg plan
martha join head corpor strategi busi develop
work ishrak ge healthcar ge capit martha name
chief integr offic lead covidien integr martha becam head
medtron restor therapi group martha graduat state degre
financ captain hockey team induct hockey fame
novemb earn call martha made remark regard
initi impress thought ahead appoint ceo comment
one thing chang focu mission
use technolog allevi pain restor health extend life
look place even emphasi innovation-driven
growth would laser-focus get organ revenu growth
rate get aggress tuck-in decis
capit alloc highest-growth segment moreov note
action increas weight averag market growth rate wamgr
believ focu serv companyand stockwel
martha highlight reinvigor diabet busi prioriti rapidli
grow market huge long-term potenti comment
confid sean salmon rest diabet busi get right
may big month first full month geoff martha
lead compani ceo heart rhythm societi meet hr showcas
number devic expect receiv approv near end
begin compani report result provid
outlook expect updat posit catalyst stock
watch
updat medtron broader cardiac rhythm heart failur crhf portfolio
cobalt/crom famili icds/crt-d
launch micra av pacemak reveal linq
icm
cardiac rhythm heart failur divis sale account total compani sale
repres largest sub-seg within cardiac vascular group cvg sale includ
implant devic pacemak defibril icd resynchron therapi
devic mechan support left ventricl assist devic lvad insert
cardiac monitor atrial fibril cathet tyrx anti-bacteri envelop remot
monitor servic softwar
overal crhf market matur categori grow low singl digit
howev believ well posit grow mid-singl digit given
product pipelin replac cycl headwind eas
number expect product launch within divis next
month includ micra av pacemak reveal linq ii icm next-gen icds/crt-
ds unclear whether host investor brief heart rhythm
societi hr scientif session given proxim earn releas
investor day june
micra av expand leadless pacemak address patient popul
receiv fda approv micra leadless pacemak april though
first full fiscal year reimburs exit year sale
annual well million product today individu need
single-chamb pacemak estim pacemak popul micra
one-tenth size tradit pacemak implant via minim invas
approach estim overal pace market billion
compani develop next-gener version micra expand
address market entir pacemak commun one product micra av
expand indic popul estim pacemak
popul novemb submit micra av expand indic
popul av block normal sinu rhythm target releas micra
av end fiscal
third version devic develop micra ar expand applic
pacemak popul micra ar sinu node diseas allow
exist micra place atrium allow sens pace atrium
approv expect sometim around fiscal
courtesi
dual chamber pace
courtesi
medtron reveal linq implant cardiac monitor icm first launch
product quit success build market busi face
headwind abbott late launch confirm rx icm first smartphone-
develop second-gener reveal linq ii icm linq ii expand
product indic current cryptogen stroke syncop atrial fibril
heart failur renal
arrhythmia moreov linq ii offer batteri life compar current linq
life bluetooth connect abil monitor addit physiolog
paramet devic expect launch late fiscal allow
protect share icm busi compani anticip product contribut
significantli cvg growth fiscal note boston scientif also plan
launch icm well
next-gen icd crt-d
medtron busi pressur due replac cycl
batteri life extend replac less often begin replac
headwind eas becom net posit moreov plan
launch next-gener cobalt chrome famili icd/crt-d earli
product improv batteri life bluesync technolog enabl
triage-hf compet boston scientif heartlog
develop extravascular ev- would compet
boston scientif emblem subcutaneous-icd believ s-icd adopt
limit larg size premium price lack capabl endovascular
devic offer includ painless post-shock pace anti-tachycardia pace atp
medtron ev-icd place sternum thu allow atp well post-
shock pace size similar convent system requir half energi
boston scientif emblem s-icd smaller size devic believ
market could potenti tripl size roughli million today
top rib
initi pivot studi evalu investig ev octob
studi includ patient site primari endpoint defibril
test success rate implant primari safeti object freedom major system
and/or procedur complic six month implant patient assess
two week three month six month everi six month thereaft compani
target approv commerci launch fiscal
expand af diamondtemp
medtron atrial fibril busi growth driver within crfh busi
main product arctic front cardiac cryoablat cathet design
pulmonari vein isol treatment patient drug refractori paroxysm af
acquir cryoablat technolog cryocath acquisit
million ablat frontier acquisit million
march close million acquisit epix epix
manufactur diamondtemp cathet temperature-control radiofrequ
ablat system cardiac arrhythmia ablat system closed-loop mean
provid physician improv feedback control ablat procedur
epix diamondtemp cathet expand exist cryoballoon offer
radiofrequ rf ablat larger billion-plu rf focal cathet segment
ablat market diamondtemp system receiv ce mark plan
europ launch two on-going trial diamond-
af diamond-af ii
diamond-af trial complet enrol octob evalu
safeti efficaci diamondtemp system patient symptomat
paroxysm atrial fibril paf pivot data expect
current enrol evalu
diamondtemp system patient persist af estim primari
outcom complet date januari estim studi complet
date april
may result guidanc
fiscal end april sale grew constant currenc basi
report basi growth driven diabet rtg
mitg cvg grew
provid initi ep guidanc along result may
substanti chang sale guidanc under-perform
diabet busi off-set better perform across three busi unit
adjust ep outlook rais reflect lower interest expens lower
may
fiscal outlook extra sell week
provid guidanc may use fiscal
year end last friday april thu everi year there extra sell week
year extra sell week fall past quarterli
benefit full year
manag offer commentari earn howev note expect
top line momentum acceler given increas benefit
product launch across divis see sever mileston valid
view lead expand pe multipl next sever year
medtron analyst day held biennial recent year new york
opportun incom ceo geoff martha detail vision
strateg initi
analyst day june manag provid updat longer-
term expect manag expect drive least organ revenu growth
incorpor view develop market grow emerg market grow
low doubl digit busi group manag expect cardiac vascular group
cvg minim invas therapi group mitg restor therapi group rtg
grow line corpor averag diabet expect grow faster
manag expect sustain annual underli oper margin expans
rang manag expect adjust ep growth
although time may felt like deliv revenu goal fx
rate mask underli perform volatil
revenu growth investor would ideal like seen
case innov compani product cycl adjust ep wise compani
gener met goal though non-oper factor like fx tax rate
prompt volatil
investor day expect head four groupscvg rtg mitg
diabet present overview respect busi pipelin
opportun futur growth
geoff martha presid ceo april
karen parkhil evp cfo
prior appoint ceo august serv evp
presid rtg global respons rtg four
divis brain therapi pain therapi specialti therapi
spine martha previous serv svp strategi busi
develop led covidien acquisit
name chief integr offic lead integr covidien
prior martha held variou leadership posit
includ manag director busi
develop earn bs financ state univers
captain hockey team
parkhil serv execut committe respons
lead global financ organ key support
relat corpor strategi busi develop join
comerica bank vice chairman
cfo parkhil previous held variou leadership posit
jpmorgan includ cfo commerci bank busi
earn bs busi administr mathemat
methodist univers univers chicago
michael mike coyl evp
bob white evp presid
brett wall evp presid
sean salmon evp presid
coyl serv evp
consult servic privat
equiti ventur capit medic
serv
division presid st jude
medic coyl also held
numer leadership posit
earn bs
western reserv univers
mba univers
white previous serv svp
presid asia pacif
develop asia pacif one
fastest grow region
join covidien
previous serv
presid respiratori
monitor solut vice-president
gener manag patient
monitor covidien also
held leadership posit ge
healthcar earn
bs market cleveland
state univers mba
wall replac geoff martha evp
presid rtg novemb
previous serv svp
brain therapi divis
within rtg join
covidien serv
presid neurovascular
wall held
posit
cr bard earn bs
administr emphasi
market univers
head diabet octob
previous serv
heart within cvg led
medtron entri drug-
elut stent market
expans tavr busi
salmon nearli year
experi industri
previou role cr bard
surgivis eurorscg life
earn bs appli physiolog
boston univers
northwestern univers
watch
launch time expect approv around end april
updat time next-gener sensor expect file
meet histor focus pharmaceut therapi increasingli
integr devic pump cgm content
possibl us pivot data could present ada meet
attd meet madrid februari minim pump expect
receiv approv geograph region around end april though
expect least hope would fda approv time ada meet
june investor brief held conjunct american diabet
associ ada meet review expect data
expect system time rang greater said believ
invest commun somewhat skeptic achiev goal way
comparison nih-fund diabet close loop trial particip use tandem
diabet slim insulin pump control-iq six month averag time-in-
rang per day time-in-rang overnight
track result compani across med-tech sector read-
thru
provid guidanc result may said note
quarter extra sell week remind use
convent view compani move convent year-end
believ investor would equal welcom chang
addit sell week meaning impact quarterli basi estim
like impact sale
note estim sale benefit contribut significantli greater size
covidien acquisit
updat ra updat day septemb manag
comment plan submit ce mark
watch
updat medtron broader cvg portfolio
updat transcathet heart valv portfolio particularli transcathet mitral
tct one largest medic confer intervent cardiolog relev
topic includ transcathet valv laa coronari stent typic
host investor brief conjunct meet
expect updat tct
fda approv low risk indic august medtron corevalv evolut
tavr platform indic symptomat sever aortic stenosi across risk
categori extrem high intermedi low indic expans came
heel strong interim data american colleg cardiolog
meet march highlight corevalv evolut use low surgic risk
continu invest next-gener tavr technolog well septemb
compani announc fda approv launch next gener evolut pro tavr
system evolut pro includ four new valv size well
extern pericardi tissu wrap help reduc incid paravalvular leak
also work new platform current name horizon product
expand indic ensur continu double-digit growth tavr busi
forese futur
also develop transcathet system treat mitral valv
manag convey believ tool box approach mitral valv diseas
need see import role mitral repair mitral replac technolog
compani index initi mitral replac believ replac
provid reliabl complet control mitral regurgit better durabl
paid million plu million mileston payment twelv
develop transcathet mitral valv replac tmvr platform
sinc renam intrepid
octob receiv fda approv start apollo transcathet mitral
valv replac trial evalu intrepid valv studi aim enrol patient
accord present updat tct confer septemb
site activ patient enrol clinicaltri gov
list primari outcom complet date octob mind seem
unrealist comment go discuss fda
possibl evalu studi design light coapt result possibl includ
mitraclip system studi random control arm also
plan integr transept deliveri system trial well current
system transap design despit transap design investig tct note
present role-in patient mortal tmvr
interest transcathet mitral valv repair preced purchas corevalv
transcathet mitral valv repair someth compani
follow long time decad follow posit readout abbott
coapt trial manag note invest mitral repair technolog
moreov said effort mitral would includ intern develop effort
well potenti activ intern program would discuss approach
due differenti approach want share detail
watch
updat surgic synergi strategi integr spinal implant enabl
nass annual meet one largest spine confer year spine
compani includ usual host meet and/or booth tour conjunct
confer
last four year stabil spine busi speed-to-
scale initi involv faster product cycl steadi cadenc new product
launch scale recent compani acquisit mazor ad robot
pre-surg plan further surgic synergi strategi integr implant
enabl technolog spine benefit pull-through core spine implant
use mazor procedur
expect updat nass
may mazor announc two strateg agreement commerci
agreement promot develop mazor product well equiti
invest mazor mazor start integr mazor robot guidanc
system spine implant navig intraop imag technolog
invest agreement includ three-step equiti invest mazor
paid million mazor outstand share follow juli
approv mazor system subsequ invest million bring
total invest mazor outstand share august compani
announc third tranch invest million bring total invest
mazor outstand share agreement assum
exclus global spine market commerci respons mazor platform
decemb close acquisit remain stake mazor
billion total gross deal valu billion
januari launch next gener mazor stealth robot
allow real-tim imag guidanc visual navig inform
interact plan inform system mazor outperform
competit drive capit equip sale within neurosurgeri
expand mazor area
manag also comment leverag mazor expand
area mazor renaiss current indic cranial procedur
recent receiv fda clearanc stealth auto-guid system smaller cranial robot
robot use lead placement db procedur electroencephalographi
eeg placement epilepsi tumor resect
courtesi
provid result updat outlook balanc year
final month get fda submiss obtain approv clearanc
diabet submiss keep eye updat timelin may fluid
chang leadership team
average time auto mode
time rang
average time auto mode
goal time rang tir
person control real-
time therapi meal handl
goal time rang tir
part submit await
day calibr
allow medicar expans
need mealtim finger stick
day calibr
dispos smaller
robot updat note plan submit ce mark
submiss also plan file us studi
would allow place initi system train gather clinic data
receiv ce mark european approv
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
